Click to Share
 

Filter News
Show All Results
News By Country
News By Tag
Dyskinesia Remove


February 2020
MoSuSaFrThWeTu
17161514131211

Public Company News

Business Press Releases

Dyskinesia Press Releases

+ Alert
+ Feed
Exclusive News
Topics Locations Industries Dates

By Neurolixis
The United States Patent and Trademark Office (USPTO) has issued a patent on NLX-112, a drug candidate developed by Neurolixis for treatment of human movement disorders, notably levodopa-induced dyskinesia in Parkinson's disease.
By Neurolixis, Inc.
The US Food and Drug Administration (FDA) gave a positive response to Neurolixis' Investigational New Drug (IND) application for NLX-112.
By Neurolixis
Neurolixis launched a collaboration with the GALA® laboratory in Castres, France. GALA® is a platform of the Rapsodee/IMT Mines Albi research facility specialized in developing novel drug formulations.

Page updated every 10 minutes


Like PRLog?
9K2K1K
Click to Share